4.8 Article

Magnetic Nanoparticle-Based Hyperthermia Mediates Drug Delivery and Impairs the Tumorigenic Capacity of Quiescent Colorectal Cancer Stem Cells

Journal

ACS APPLIED MATERIALS & INTERFACES
Volume 13, Issue 14, Pages 15959-15972

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsami.0c21349

Keywords

magnetic hyperthermia; magnetic nanoparticles; doxorubicin; cancer stem cells; colorectal cancer

Funding

  1. European Research Council (starting grant ICARO) [678109]
  2. AIRC Foundation [AIRC IG-14527, AIRC IG-21445, AIRC IG-21492]
  3. European Research Council (ERC) [678109] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

The combination therapy of magnetic hyperthermia and local chemotherapy shows efficacy in inhibiting dormant cancer stem cells in colorectal cancer, with promising results in colony-forming assays and tumor formation studies. These findings highlight the potential of this treatment approach as an effective personalized cancer treatment against quiescent cancer stem cells.
Cancer stem cells (CSCs) are the tumor cell subpopulation responsible for resistance to chemotherapy, tumor recurrence, and metastasis. An efficient therapy must act on low proliferating quiescent-CSCs (q-CSCs). We here investigate the effect of magnetic hyperthermia (MHT) in combination with local chemotherapy as a dual therapy to inhibit patient-derived colorectal qCR-CSCs. We apply iron oxide nanocubes as MHT heat mediators, coated with a thermoresponsive polymer (TR-Cubes) and loaded with DOXO (TR-DOXO) as a chemotherapeutic agent. The thermoresponsive polymer releases DOXO only at a temperature above 44 degrees C. In colony-forming assays, the cells exposed to TR-Cubes with MHT reveal that qCR-CSCs struggle to survive the heat damage and, with a due delay, restart the division of dormant cells. The eradication of qCR-CSCs with a complete stop of the colony formation was achieved only with TR-DOXO when exposed to MHT. The in vivo tumor formation study confirms the combined effects of MHT with heat-mediated drug release: only the group of animals that received the CR-CSCs pretreated, in vitro, with TR-DOXO and MHT lacked the formation of tumor even after several months. For DOXO-resistant CR-CSCs cells, the same results were shown, in vitro, when choosing the drug oxaliplatin rather than DOXO and applying MHT. These findings emphasize the potential of our nanoplatforms as an effective patient-personalized cancer treatment against qCR-CSCs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available